A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

Ozempic® is now covered by most public formularies across Canada

map-canada Created with Sketch.

Select a province or formulary body to find out additional details about public coverage.

Ozempic® is also covered by most private formularies across Canada.

Alberta Drug Benefit List (ADBL)

Special Authorization: As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on: a sufficient trial (i.e., a minimum of 6 months) of metformin, AND a sulfonylurea, AND for whom insulin is not an option; OR for whom these products are contraindicated. Special authorization may be granted for 24 months.7

Ontario Drug Benefit (ODB)

General Benefit with a Therapeutic Note: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.8

Quebec (RAMQ*)

Exceptional Medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.10

* Official mark of the Régie de l’assurance maladie du Québec.

New Brunswick (NBPDP)

Special Authorization: For the treatment of type 2 diabetes mellitus as a second drug added to metformin for patients who have inadequate glycemic control on metformin; or third drug added to metformin and a sulfonylurea for patients who have inadequate glycemic control on metformin and a sulfonylurea. Clinical note: for patients who cannot take metformin due to contraindications or intolerances, details must be provided.11

PEI Pharmacare

Special Authorization: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.9

Newfoundland and Labrador (NLPDP)

Special Authorization: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.12

Non-insured Health Benefits (NIHB)

Open Benefit with a Therapeutic Note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.13

Yukon Territory (Clinical Services Plan)

Exceptional Drug Status: In addition to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea.14

Northwest Territories (EHB)

Open Benefit with a Therapeutic Note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.13,15

Nunavut (EHB)

Open Benefit with a Therapeutic Note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.13,16

Veteran Affairs Canada (PDP)

Open Benefit: Standard benefit available Canada-wide for eligible clients.17

AB, Alberta; EHB, extended health benefit; NB, New Brunswick; NIHB, Non-Insured Health Benefits; NL, Newfoundland and Labrador; NT, Northwest Territories; NU, Nunavut; ON, Ontario; PE, Prince Edward Island; PDP, prescription drug program; QC, Québec; RAMQ, Régie de l'assurance maladie du Québec; VAC, Veterans Affairs Canada; YT, Yukon.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225